TelyRx Holdings Inc. GAAP EPS of -$0.06
At a glance
- $TELYF today−11.4%last $1.67
- 52-week range7.3% above low$1.56 – $2.02
- In the headline$0.06Amount
- Coverage1 this week1 in 30 days · thin coverage — a small sample
- Sector scannerCalmHealth Care
What it means
- What to watch: The headline hangs on one number ($0.06) — one data point is a snapshot, so the trailing trend is the context it needs.
- How the stock is trading: $TELYF -11.43% in the latest session.
- Timing: Weekend news: the change beside it is Friday's, and Monday's open is the first session that gets a say. Market holidays are not detected.
Where the stock stands
$TELYF last traded at $1.67, -11.43% on the session. That puts it 17% shy of its 52-week high of $2.02 and 7.3% clear of its low of $1.56 — in the lower part of the range. Over the year it has ranged 29% from low to high: a moderate band — lively, not wild. These are latest-session quotes, not live prices — the live tape is on the $TELYF page.
How much coverage it is getting
Nothing else on $TELYF in the last 30 days: this is the only story Wook has filed, so there is no run to measure it against yet. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
With earnings, the number matters less than the number versus expectations — and guidance often matters more than both. A beat paired with a soft outlook can still get a cold reception. On Wook's supply-chain scanner, Health Care reads calm today — no unusual stress in the filings and disclosures it watches. The scanner equivalent of a quiet night shift.
What to watch next
The $TELYF page has the full chart, the filings and the valuation model behind every figure here. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. And Wook AI, up top, will happily do the math — how far $TELYF sits from its high, or how this week's coverage stacks up.
Discussion
No one has weighed in yet. Start the discussion on this story.